CiteULike: guhjy's Kastelein:JJ [12 articles]

Combination statin-fibrate therapy: safety aspects.

Diabetes, obesity & metabolism, Vol. 11, No. 2. (February 2009), pp. 89-94.

by R. Franssen, M. Vergeer, E. S. Stroes, J. J. Kastelein

posted to statin fibrate by guhjy on 2009-11-15 02:59:30 as

Surrogate markers in clinical trials--challenges and opportunities.

Atherosclerosis, Vol. 206, No. 1. (September 2009), pp. 8-16.

by Raphaël Duivenvoorden, Eric de Groot, Erik S. Stroes, John J. Kastelein

posted to surrogate rct by guhjy on 2009-09-02 07:00:55 as

along with 1 person booker

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Lancet, Vol. 373, No. 9670. (4 April 2009), pp. 1175-1182.

by P. M. Ridker, E. Danielson, F. A. Fonseca, et al.J. Genest, A. M. Gotto, J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. Macfadyen, B. G. Nordestgaard, J. Shepherd, J. T. Willerson, R. J. Glynn,

posted to crp cv rct statin by guhjy on 2009-05-27 05:31:53 as

along with 1 person booker

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

N Engl J Med, Vol. 359, No. 21. (20 November 2008), pp. 2195-2207.

by Paul M. Ridker, Eleanor Danielson, Francisco A. H. Fonseca, et al.Jacques Genest, Antonio M. Gotto, John J. P. Kastelein, Wolfgang Koenig, Peter Libby, Alberto J. Lorenzatti, Jean G. MacFadyen, Borge G. Nordestgaard, James Shepherd, James T. Willerson, Robert J. Glynn, the JUPITER Study Group

posted to crp cv rct statin by guhjy on 2008-11-21 09:45:15 as

along with 6 people timsenior nm61591 lula djmonstermo shoshin fkz1

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

The New England journal of medicine, Vol. 356, No. 16. (19 April 2007), pp. 1620-1630.

by J. J. Kastelein, S. I. van Leuven, L. Burgess, et al.G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, C. L. Shear, W. T. Duggan, M. L. Bots,

posted to cad hdl rct surrogate by guhjy on 2008-08-06 07:37:54 as

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

N Engl J Med (30 March 2008), NEJMoa0800742.

by John J. Kastelein, Fatima Akdim, Erik S. Stroes, et al.Aeilko H. Zwinderman, Michiel L. Bots, Anton F. Stalenhoef, Frank L. Visseren, Eric J. Sijbrands, Mieke D. Trip, Evan A. Stein, Daniel Gaudet, Raphael Duivenvoorden, Enrico P. Veltri, David A. Marais, Eric de Groot, The E. Investigators

posted to ldl lipid rct statin by guhjy on 2008-08-06 04:47:46 as

along with 3 people A_Hoogendam omalbam rdragu

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

The New England journal of medicine, Vol. 357, No. 13. (27 September 2007), pp. 1301-1310.

by P. Barter, A. M. Gotto, J. C. LaRosa, et al.J. Maroni, M. Szarek, S. M. Grundy, J. J. Kastelein, V. Bittner, J. C. Fruchart,

posted to cv hdl lipid by guhjy on 2008-07-10 02:22:26 as

Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study

J Am Coll Cardiol, Vol. 51, No. 15. (15 April 2008), pp. 1448-1454.

by James Shepherd, John J. Kastelein, Vera Bittner, et al.Prakash Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea Zuckerman, Nanette K. Wenger, For

posted to cad ckd cv rct statin uae by guhjy on 2008-07-08 05:28:51 as

Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 22, No. 6. (June 2007), pp. 1578-1586.

by R. C. Ozsoy, W. A. van der Steeg, J. J. Kastelein, L. Arisz, M. G. Koopman

posted to ckd lipid statin by guhjy on 2008-06-29 04:38:48 as

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Clinical journal of the American Society of Nephrology : CJASN, Vol. 2, No. 6. (November 2007), pp. 1131-1139.

by J. Shepherd, J. J. Kastelein, V. Bittner, et al.P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger,

posted to cad ckd lipid rct statin by guhjy on 2008-06-17 04:22:55 as

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Circulation, Vol. 117, No. 23. (10 June 2008), pp. 3002-3009.

by J. J. Kastelein, W. A. van der Steeg, I. Holme, et al.M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, M. Szarek, J. C. LaRosa, T. R. Pedersen, S. M. Grundy, ,

posted to cad cv hdl lipid by guhjy on 2008-06-13 13:30:15 as

Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies.

European journal of human genetics : EJHG, Vol. 16, No. 9. (September 2008), pp. 1111-1116.

by Jeroen B. van der Net, A. Cecile Janssens, Marinus J. Eijkemans, John J. Kastelein, Eric J. Sijbrands, Ewout W. Steyerberg

posted to cox genetics lr snp by guhjy on 2008-05-09 03:45:47 as

Sort by:
Order:	Default Ascending Descending
Empty fields:	Default First Last

	Combination statin-fibrate therapy: safety aspects. [My Copy] Diabetes, obesity & metabolism, Vol. 11, No. 2. (February 2009), pp. 89-94. by R. Franssen, M. Vergeer, E. S. Stroes, J. J. Kastelein posted to statin fibrate by guhjy on 2009-11-15 02:59:30 as
	Surrogate markers in clinical trials--challenges and opportunities. [My Copy] Atherosclerosis, Vol. 206, No. 1. (September 2009), pp. 8-16. by Raphaël Duivenvoorden, Eric de Groot, Erik S. Stroes, John J. Kastelein posted to surrogate rct by guhjy on 2009-09-02 07:00:55 as along with 1 person booker
	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. [My Copy] Lancet, Vol. 373, No. 9670. (4 April 2009), pp. 1175-1182. by P. M. Ridker, E. Danielson, F. A. Fonseca, et al.J. Genest, A. M. Gotto, J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. Macfadyen, B. G. Nordestgaard, J. Shepherd, J. T. Willerson, R. J. Glynn, posted to crp cv rct statin by guhjy on 2009-05-27 05:31:53 as along with 1 person booker
	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein [My Copy] N Engl J Med, Vol. 359, No. 21. (20 November 2008), pp. 2195-2207. by Paul M. Ridker, Eleanor Danielson, Francisco A. H. Fonseca, et al.Jacques Genest, Antonio M. Gotto, John J. P. Kastelein, Wolfgang Koenig, Peter Libby, Alberto J. Lorenzatti, Jean G. MacFadyen, Borge G. Nordestgaard, James Shepherd, James T. Willerson, Robert J. Glynn, the JUPITER Study Group posted to crp cv rct statin by guhjy on 2008-11-21 09:45:15 as along with 6 people timsenior nm61591 lula djmonstermo shoshin fkz1
	Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. [My Copy] The New England journal of medicine, Vol. 356, No. 16. (19 April 2007), pp. 1620-1630. by J. J. Kastelein, S. I. van Leuven, L. Burgess, et al.G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, C. L. Shear, W. T. Duggan, M. L. Bots, posted to cad hdl rct surrogate by guhjy on 2008-08-06 07:37:54 as
	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia [My Copy] N Engl J Med (30 March 2008), NEJMoa0800742. by John J. Kastelein, Fatima Akdim, Erik S. Stroes, et al.Aeilko H. Zwinderman, Michiel L. Bots, Anton F. Stalenhoef, Frank L. Visseren, Eric J. Sijbrands, Mieke D. Trip, Evan A. Stein, Daniel Gaudet, Raphael Duivenvoorden, Enrico P. Veltri, David A. Marais, Eric de Groot, The E. Investigators posted to ldl lipid rct statin by guhjy on 2008-08-06 04:47:46 as along with 3 people A_Hoogendam omalbam rdragu
	HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. [My Copy] The New England journal of medicine, Vol. 357, No. 13. (27 September 2007), pp. 1301-1310. by P. Barter, A. M. Gotto, J. C. LaRosa, et al.J. Maroni, M. Szarek, S. M. Grundy, J. J. Kastelein, V. Bittner, J. C. Fruchart, posted to cv hdl lipid by guhjy on 2008-07-10 02:22:26 as
	Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study [My Copy] J Am Coll Cardiol, Vol. 51, No. 15. (15 April 2008), pp. 1448-1454. by James Shepherd, John J. Kastelein, Vera Bittner, et al.Prakash Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea Zuckerman, Nanette K. Wenger, For posted to cad ckd cv rct statin uae by guhjy on 2008-07-08 05:28:51 as
	Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. [My Copy] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 22, No. 6. (June 2007), pp. 1578-1586. by R. C. Ozsoy, W. A. van der Steeg, J. J. Kastelein, L. Arisz, M. G. Koopman posted to ckd lipid statin by guhjy on 2008-06-29 04:38:48 as
	Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. [My Copy] Clinical journal of the American Society of Nephrology : CJASN, Vol. 2, No. 6. (November 2007), pp. 1131-1139. by J. Shepherd, J. J. Kastelein, V. Bittner, et al.P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, posted to cad ckd lipid rct statin by guhjy on 2008-06-17 04:22:55 as
	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. [My Copy] Circulation, Vol. 117, No. 23. (10 June 2008), pp. 3002-3009. by J. J. Kastelein, W. A. van der Steeg, I. Holme, et al.M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, M. Szarek, J. C. LaRosa, T. R. Pedersen, S. M. Grundy, , posted to cad cv hdl lipid by guhjy on 2008-06-13 13:30:15 as
	Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies. [My Copy] European journal of human genetics : EJHG, Vol. 16, No. 9. (September 2008), pp. 1111-1116. by Jeroen B. van der Net, A. Cecile Janssens, Marinus J. Eijkemans, John J. Kastelein, Eric J. Sijbrands, Ewout W. Steyerberg posted to cox genetics lr snp by guhjy on 2008-05-09 03:45:47 as

guhjy's Kastelein:JJ [12 articles] Export Sort

guhjy's tags

ckd	1745
rct	1208
dn	1177
dm	1073
cancer	1068
ma	981
cv	940
hd	860
tgfb	857
snp	773
ros	707
bp	647
kidney	533
meta-analysis	518
mouse	510
uae	508
stats	480
software	468
pt	458
mirna	450
genetics	450
proteomics	415
mortality	413
rat	402
1	391
fbl	386
inflammation	378
tw	378
mtor	364
proteinuria	357
pcr	356
akt	351
mc	351
acei	343
method	340
db	337
irs	333
gdl	332
inhibitor	329
test	325
arb	321
apoptosis	321
age	318
urine	318
aging	315
ms	314
aii	310
hcv	308
r	297
hg	293
biomarker	288
pi3k	284
ppi	282
bias	278
bayes	275
aki	272
gwa	271
emt	268
s6k	266
rnai	258
egfr	256
nutrition	255
ub	248
p53	246
fibrosis	242
erk	238
obesity	237
smad	234
cox	229
drug	225
pbmc	223
hcc	217
hypoxia	216
metab	215
gn	210
nfkb	209
herb	205
stz	199
collagen	197
albumin	190
hif	187
lc	187
pkc	181
longitudinal	179
pubmed	179
lmm	178
p38	176
gfr	175
ua	171
epigenetics	169
book	168
bioinf	167
japan	166
gender	163
cea	163
power	163
rage	162
dna-damage	162
lead	160
cadmium	159
genomics	156
ref	152
ctgf	150
vitamin-d	149
stata	147
liver	147
company	146
mt	146
network	146
diet	138
screening	137
insulin	137
rt	136
phosphorylation	135
seq	133
no	132
stat	130
esrd	129
kinase	128
cell-cycle	128
go	128
protein	127
pathway	127
systems-biology	124
statin	121
lipid	119
creatinine	117
proliferation	113
senescence	112
podocyte	111
gene-therapy	110
imaging	110
nox	109
mapk	109
tnf	107
hypertrophy	105
pparg	105
fish	104
p21	104
cad	103
regression	103
gfr-formula	102
pd	102
case-control	102
imputation	101
ampk	100
multiplicity	100
observational	98
at1	98
ko	98
plasmid	98
sirt	97
pediatric	96
rx	96
methylation	96
cloning	96
recurrent	94
betel	93
src	93
blood	93
review	92
chf	92
website	91
nhanes	91
anemia	89
immunity	89
phenotype	88
autophagy	87
diagnosis	87
lr	86
toxicology	86
uti	85
epo	85
ebm	84
cytokine	84
china	83
ca	83
p	83
environment	82
oat	81
cachexia	81
nonp	81
hapmap	80
gout	80
qms	78
primer	78
signaling	76
col4	74
foxo	74
egf	74
surrogate	74
promoter	74
ace	73
gpcr	73
eif	73
missing	73
stone	72
4ebp	72
lpd	72
gene-list	72
eqtl	72
cox2	72
hts	72
p-value	71
mv	71
mgo	70
phd	70
jnk	70
salt	70
metformin	70
glycemia	69
tin	67
uuo	67
normalization	66
fluorescence	66
uncertainty	66
enddysf	65
chinese	65
ifn	65
mirna-target	65
translation	65
pe	65
association	64
hsp	64
shc	64
pla2	64
acid-base	63
yeast	63
llcpk1	63
2dge	63
causation	63
simulation	62
me	62
pdgf	62
smoking	62
oglcnac	62
nrk49f	62
pai1	62
avf	61
confounding	61
vegf	61
ptm	61
mmp	61
cost	60
change	60
melamine	60
sas	60
infection	60
crp	60
pld	60
hk2	60
outcome	60
oral	60
alcohol	58
iron	58
rho	58
model-selection	57
urate-transporter	57
aceiarb	57
pls	57
robust	57
rapamycin	57
cyclin-d1	57
achr	56
semantic	56
calibration	56
stem-cell	55
competing-risk	55
goldstd	55
ncrna	55
estrogen	55
renoprotection	55
ace2	55
ratio	55
ckd-progression	54
function	54
bone	54
workflow	54
dipstick	53
std	53
hsc	53
qc	53
k	53
il6	53
p27	53
hdac	52
histone	52
fgf	52
dimerization	52
atm	52
tf	52
lod	51
hepatocyte	51
pth	51
normoalbuminuria	51
epidemiology	51
ab	51
graph	50
adpkd	50
matlab	50
arsenic	50
mercury	50
reasoning	50
risk-ratio	50
wnt	50
epistasis	49
biosensor	49
gene-environment	49
pdk	49
klotho	49
antibiotics	49
ngal	48
ffpe	48
irs1	48
enos	48
nrk52e	48
breakpoint	48
ukm	48
core-curriculum	48
endothelium	48
spot-urine	48
prevention	47
aldosterone	47
pooling	47
joint-model	47
mtorc1	47
ras	47
aspirin	46
cystatin	46
hgf	46
protein-microarray	46
metal	46
dub	46
fdr	46
er-stress	46
writing	45
fgf23	45
semip	45
dbdb	45
ecm	45
tgfbr	45
diuretics	44
cnv	44
interaction	44
stroke	44
variability	44
mesangial	44
ancova	44
ccb	44
sumo	44
klf	43
design	43
sle	43
bia	43
na	43
agreement	42
roc	42
asia	42
fibronectin	42
vsmc	42
good	42
bmi	42
catenin	42
icu	42
fuzzy	41
qtl	41
gene-targeting	41
proteasome	41
tlr	40
risk	40
hyperfiltration	40
sage	40
ap1	40
rca	40
wga	40
alignment	40
tea	40
urinalysis	39
igf	39
angiogenesis	39
rsk	39
glut	39
dry-bw	39
protein-complex	39
coffee	39
omics	39
antisense	39
gsk3	38
snx	38
myc	38
emr	38
rvh	38
igan	38
mtorc2	38
haplotype	37
bh4	37
fabp	37
hematuria	37
gsk	37
megalin	37
adh	37
adenosine	37
propensity	37
inflammasome	36
nephrotoxicity	36
animal	36
exercise	36
cardiorenal	36
il1	36
s100b	36
web20	36
creb	35
pka	35
threshold	35
annotation	35
cre	35
subgroup	35
adduct	35
sp1	35
candidate-gene	35
reverse-epidemiology	35
calcification	35
chemogenomics	35
sglt	35
effect-size	34
msm	34
sepsis	34
cross-species	34
attrition	34
pathology	34
igf1	34
pp2a	34
bmp	33
zeb	33
rtk	33
cage	33
ns	33
integrin	33
ecology	33
browser	33
et	33
sarcopenia	33
macrophage	32
ai	32
fc	32
addgene	32
text-mining	32
affy	32
transactivation	32
zfn	32
set	32
steroid	32
agt	32
end-point	32
aa	32
orbitrap	32
acidosis	31
risk-difference	31
cr	31
hospitalization	31
frailty	31
gllamm	31
blast	31
family	31
emsa	31
heritability	31
gsh	31
abp	31
nutrient	31
silac	31
reporter	31
renin	30
geo	30
staging	30
transporter	30
knockout	30
pten	30
notch	30
s100	30
human	30
mw	30
carcinogen	30
membrane-protein	30
grn	30
nicotinic	29
validation	29
virus	29
ub-ligase	29
sgk	29
extraction	29
perindopril	29
3	29
thesis	29
ndrd	29
pharmacogenetics	29
muscarinic	28
gee	28
acetylation	28
race	28